4.81
0.21%
+0.010
After Hours:
4.84
0.03
+0.62%
Immucell Corp. stock is currently priced at $4.81, with a 24-hour trading volume of 27,077.
It has seen a +0.21% increased in the last 24 hours and a -4.75% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.83 pivot point. If it approaches the $4.72 support level, significant changes may occur.
Previous Close:
$4.80
Open:
$4.79
24h Volume:
27,077
Market Cap:
$20.10M
Revenue:
$17.47M
Net Income/Loss:
$-5.77M
P/E Ratio:
-6.2468
EPS:
-0.77
Net Cash Flow:
$-6.57M
1W Performance:
-11.58%
1M Performance:
-4.75%
6M Performance:
+1.02%
1Y Performance:
-6.42%
Immucell Corp. Stock (ICCC) Company Profile
Name
Immucell Corp.
Sector
Industry
Phone
207 878 2770
Address
56 Evergreen Drive, Portland, ME
Immucell Corp. Stock (ICCC) Latest News
ImmuCell Corporation (NASDAQ:ICCC) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Earnings call: ImmuCell reports sales increase to $7.2 million - Investing.com
Investing.com
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024 - 14.05.2024 - wallstreet:online
wallstreet:online
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024
GlobeNewswire Inc.
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above 200-Day Moving Average of $5.02 - Defense World
Defense World
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
GlobeNewswire Inc.
Immucell Corp. Stock (ICCC) Financials Data
Immucell Corp. (ICCC) Revenue 2024
ICCC reported a revenue (TTM) of $17.47 million for the quarter ending December 31, 2023, a -5.90% decline year-over-year.
Immucell Corp. (ICCC) Net Income 2024
ICCC net income (TTM) was -$5.77 million for the quarter ending December 31, 2023, a -131.56% decrease year-over-year.
Immucell Corp. (ICCC) Cash Flow 2024
ICCC recorded a free cash flow (TTM) of -$6.57 million for the quarter ending December 31, 2023, a -18.98% decrease year-over-year.
Immucell Corp. (ICCC) Earnings per Share 2024
ICCC earnings per share (TTM) was -$0.75 for the quarter ending December 31, 2023, a -141.94% decline year-over-year.
About Immucell Corp.
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Cap:
|
Volume (24h):